These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23600828)

  • 1. Leishmania expressed lipophosphoglycan interacts with Toll-like receptor (TLR)-2 to decrease TLR-9 expression and reduce anti-leishmanial responses.
    Srivastava S; Pandey SP; Jha MK; Chandel HS; Saha B
    Clin Exp Immunol; 2013 Jun; 172(3):403-9. PubMed ID: 23600828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan.
    Halliday A; Bates PA; Chance ML; Taylor MJ
    Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2.
    Becker I; Salaiza N; Aguirre M; Delgado J; Carrillo-Carrasco N; Kobeh LG; Ruiz A; Cervantes R; Torres AP; Cabrera N; González A; Maldonado C; Isibasi A
    Mol Biochem Parasitol; 2003 Aug; 130(2):65-74. PubMed ID: 12946842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptors and CD40 modulate each other's expression affecting Leishmania major infection.
    Chandel HS; Pandey SP; Shukla D; Lalsare K; Selvaraj SK; Jha MK; Saha B
    Clin Exp Immunol; 2014 May; 176(2):283-90. PubMed ID: 24387292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling.
    de Veer MJ; Curtis JM; Baldwin TM; DiDonato JA; Sexton A; McConville MJ; Handman E; Schofield L
    Eur J Immunol; 2003 Oct; 33(10):2822-31. PubMed ID: 14515266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKT cell activation by Leishmania mexicana LPG: Description of a novel pathway.
    Zamora-Chimal J; Fernández-Figueroa EA; Ruiz-Remigio A; Wilkins-Rodríguez AA; Delgado-Domínguez J; Salaiza-Suazo N; Gutiérrez-Kobeh L; Becker I
    Immunobiology; 2017 Feb; 222(2):454-462. PubMed ID: 27523746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraspecies Polymorphisms in the Lipophosphoglycan of
    Vieira TDS; Rugani JN; Nogueira PM; Torrecilhas AC; Gontijo CMF; Descoteaux A; Soares RP
    Front Cell Infect Microbiol; 2019; 9():240. PubMed ID: 31355149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interdependencies between Toll-like receptors in Leishmania infection.
    Shukla D; Patidar A; Sarma U; Chauhan P; Pandey SP; Chandel HS; Bodhale N; Ghosh SK; Guzman CA; Ebensen T; Silvestre R; Sarkar A; Saha B; Bhattacharjee S
    Immunology; 2021 Sep; 164(1):173-189. PubMed ID: 33964011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two biochemically distinct lipophosphoglycans from Leishmania braziliensis and Leishmania infantum trigger different innate immune responses in murine macrophages.
    Ibraim IC; de Assis RR; Pessoa NL; Campos MA; Melo MN; Turco SJ; Soares RP
    Parasit Vectors; 2013 Mar; 6():54. PubMed ID: 23497381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated bisacycloxypropylcysteine, a diacylated lipopeptide ligand of TLR6, plays a host-protective role against experimental Leishmania major infection.
    Pandey SP; Chandel HS; Srivastava S; Selvaraj S; Jha MK; Shukla D; Ebensen T; Guzman CA; Saha B
    J Immunol; 2014 Oct; 193(7):3632-43. PubMed ID: 25194056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leishmania infantum lipophosphoglycan induced-Prostaglandin E
    Lima JB; Araújo-Santos T; Lázaro-Souza M; Carneiro AB; Ibraim IC; Jesus-Santos FH; Luz NF; Pontes SM; Entringer PF; Descoteaux A; Bozza PT; Soares RP; Borges VM
    Sci Rep; 2017 Oct; 7(1):14321. PubMed ID: 29084985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autophagy downstream of endosomal Toll-like receptor signaling in macrophages is a key mechanism for resistance to
    Franco LH; Fleuri AKA; Pellison NC; Quirino GFS; Horta CV; de Carvalho RVH; Oliveira SC; Zamboni DS
    J Biol Chem; 2017 Aug; 292(32):13087-13096. PubMed ID: 28607148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UNC93B1 and nucleic acid-sensing Toll-like receptors mediate host resistance to infection with Leishmania major.
    Schamber-Reis BL; Petritus PM; Caetano BC; Martinez ER; Okuda K; Golenbock D; Scott P; Gazzinelli RT
    J Biol Chem; 2013 Mar; 288(10):7127-36. PubMed ID: 23325805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation.
    Katebi A; Varshochian R; Riazi-Rad F; Ganjalikhani-Hakemi M; Ajdary S
    Biomed Pharmacother; 2021 May; 137():111276. PubMed ID: 33485119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation Pathways of Murine Macrophages by Lipophosphoglycan from Strains of
    Mançur Santos V; Goicochea AMC; Soares Neto AJ; Jesus Santos FH; Lobo da Silva J; Araújo-Santos T; Paiva Farias L; Brodskyn CI; M Borges V; Pedro Soares R; Berlink Lima J
    ACS Infect Dis; 2024 Oct; 10(10):3544-3552. PubMed ID: 39313410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin-derived macrophages from Leishmania major-susceptible mice exhibit interleukin-12- and interferon-gamma-independent nitric oxide production and parasite killing after treatment with immunostimulatory DNA.
    von Stebut E; Belkaid Y; Nguyen B; Wilson M; Sacks DL; Udey MC
    J Invest Dermatol; 2002 Sep; 119(3):621-8. PubMed ID: 12230504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transmission blocking vaccine studies in leishmaniasis: I. Lipophosphoglycan is a promising transmission blocking vaccine molecule against cutaneous leishmaniasis.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):84-9. PubMed ID: 11682952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
    Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
    Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies.
    Späth GF; Lye LF; Segawa H; Turco SJ; Beverley SM
    Infect Immun; 2004 Jun; 72(6):3622-7. PubMed ID: 15155672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance Against
    Lopes ME; Dos Santos LM; Sacks D; Vieira LQ; Carneiro MB
    Front Immunol; 2021; 12():730437. PubMed ID: 34745100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.